Stock Taper
SCREENER COMPARE ANY 2 STOCKS
STRO
SUTRO BIOPHARMA, INC.
NASDAQ
$20.45
▼ DOWN 4.04% (-0.86)

KEY STATISTICS

Market Cap$197.90 M
52w High$43.85
52w Low$7.15
Dividend Yield—
Frequency—
P/E-1.18
Volume143.82K
Shares Out.9.68M

COMPANY

LEADERSHIP

Jane Chung
CHIEF EXECUTIVE
Jane Chung

COMPENSATION 2026

Salary$239,693
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$1,431,618
Total$1,671,311

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 27, 2018
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
128

PRICE TARGET

Target High$60.00
Target Low$43.00
Target Median$50.00
Target Consensus$51.00

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$13.61M
NOV
5
THU

SPLIT RECORD

DATETYPERATIO
2025-12-03Reverse1:10

PRICE

$20.45 ▼ DOWN 4.04% (−$0.86)
OVERLAYS
$20.40$20.80$21.20$21.609:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM20.45

About Sutro Biopharma, Inc.

https://www.sutrobio.com ↗

Sutro Biopharma, a clinical-stage biotech in South San Francisco, develops protein therapeutics for cancer and autoimmune diseases using cell-free synthesis, with ADC candidates in Phase 1 trials and collaborations with Merck and Celgene.

INDUSTRY

Biotechnology

A PRODUCT SUTRO BIOPHARMA, INC. IS KNOWN FOR

STRO-004
STRO-004

STRO-004, Sutro Biopharma’s lead ADC targeting Tissue Factor, is in Phase 1 trials for various solid tumors including lung, head and neck, cervical, colorectal, pancreatic, and bladder cancers.

COMPETITORS

COMPETITOR
ADCT COMPARE
GILD COMPARE
PYXS COMPARE

Revenue by Products

IconPRODUCTQ3-2018Q4-2018Q2-2025Q3-2025
Collaboration Revenue— $18.43M — —
Operating Segments— — $63.74M $9.69M ▼
Other Revenue$912K $654K ▼— —

ETFS HOLDING THIS STOCK

ETFS HOLDING
75
LISTED HERE
13
RANKED BY POSITION SIZE
VTS.AX
0.00% · 501.5K
XSU.TO
0.01% · 401.6K
FESM
0.05% · 150.6K
OMFS
0.21% · 28.7K
ZPRR.DE
0.01% · 22.6K
XRSU.L
0.01% · 14.6K
GSSC
0.02% · 12.6K
RSSL
0.01% · 7.5K
ETLZ.DE
0.02% · 1.9K
PQ
PQSG
0.18% · 1.4K
WCEO
0.15% · 936
URTY
0.00% · 648
RESM
0.01% · 29

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
130
TOP 12 OF 130 · RANKED BY POSITION SIZE
Blackrock Inc.
6.9M sh · $20.25M
Suvretta Capital Management, LLC
6.5M sh · $5.63M
Kynam Capital Management, LP
5.1M sh · $4.42M
Millennium Management LLC
4.5M sh · $3.93M
Vanguard Group Inc
3.7M sh · $3.2M
Acadian Asset Management LLC
3.4M sh · $2.94M
Velan Capital Investment Management LP
3.1M sh · $2.71M
Tang Capital Management LLC
2.8M sh · $2.46M
Merck & Co., Inc.
2.7M sh · $2.37M
Vestal Point Capital, LP
2.6M sh · $2.26M
Eversept Partners, LP
2.3M sh · $1.99M
Samsara Biocapital, LLC
2.2M sh · $1.91M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR
Wigginton Jon Marc
Purchase · 10.0K shares
2026-06-05
★
DIRECTOR
Petree Daniel H
Purchase · 10.0K shares
2026-06-05
★
DIRECTOR
PANEK JAMES P
Purchase · 10.0K shares
2026-06-05
★
DIRECTOR
Lobacki Joseph M
Purchase · 10.0K shares
2026-06-05

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 2
BUY 2
MARKET OUTPERFORM 1
OVERWEIGHT 1
6 GRADES IN THE LAST 12 MONTHS
Citizens MARKET OUTPERFORM Wedbush OUTPERFORM Leerink Partners OUTPERFORM HC Wainwright & Co. BUY Deutsche Bank BUY Wells Fargo OVERWEIGHT

SECTORS PEERS

PEERPRICE
STTK$7.04COMPARE
ARTV$11.09COMPARE
IFRX$2.23COMPARE
CNTB$2.23COMPARE
GUTS$0.66COMPARE
DTIL$7.78COMPARE
KLRS$4.03COMPARE
PLRX$1.11COMPARE